Plain-English translation of NCT07041099 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new subcutaneous injection designed to treat Sjogren's disease by targeting specific immune cells that may be causing the condition. The study will enroll about 36 people with active, moderate to severe Sjogren's disease and monitor how well this medication works and how safe it is. This is an early-stage trial (Phase 1b), meaning the treatment is still being studied to understand the best dose and how it affects patients.
Sjogren's disease causes the immune system to attack the body's moisture-producing glands, leading to dry eyes and mouth, along with other symptoms. Current treatments don't work well enough for everyone, so researchers are developing this medication as a new option to help control the disease by working with the immune system in a different way.
You likely qualify if…
You likely don't qualify if…
You would receive subcutaneous injections of (given under the skin) at regular intervals during the study. The trial has two parts: Part A involves starting at a low dose and gradually increasing it to find the safest and most effective dose, and Part B involves giving more people the dose determined to work best. You will have regular visits for blood tests, physical exams, and assessments of your Sjogren's disease symptoms to monitor how well the treatment is working and any side effects.
AI-generated summary from trial data · Aug 23, 2026 · Not medical advice
United States